News
SYBX
1.780
-1.11%
-0.020
Weekly Report: what happened at SYBX last week (0318-0322)?
Weekly Report · 2d ago
Synlogic Appoints James Flynn to Board Amidst Director Resignations
TipRanks · 6d ago
Hold Rating on Synlogic Amidst Lead Program Discontinuation and Strategic Uncertainties
TipRanks · 03/21 06:18
Synlogic Raised to Neutral From Sell by HC Wainwright & Co.
Dow Jones · 03/20 16:17
HC Wainwright & Co. Upgrades Synlogic to Neutral
Benzinga · 03/20 16:08
H.C. Wainwright upgrades Synlogic (SYBX) to a Hold
TipRanks · 03/20 15:35
Synlogic Inc reports results for the quarter ended in December - Earnings Summary
Synlogic Inc reports results for the quarter ended in December. Revenue rose 2,512.3% to $2.77 million from a year ago. The company reported a quarterly adjusted loss of $1.71 per share. The mean expectation of three analysts was for a loss of 97 cents.
Reuters · 03/19 13:32
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/19 12:10
Synlogic GAAP EPS of -$1.71 misses by $0.74, revenue of $2.77M beats by $0.04M
Seeking Alpha · 03/19 11:13
Synlogic Q4 EPS $(1.71) Misses $(0.97) Estimate, Sales $2.77M Beat $2.73M Estimate
Synlogic reported quarterly losses of $1.71 per share. The company reported quarterly sales of $2.77 million which beat the analyst consensus estimate by 1.43%. The company missed the analyst estimate by 76.29 percent. Synlogic also reported a 52.5 percent increase in sales to $106.00 million.
Benzinga · 03/19 11:05
Press Release: Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results. The Company recently announced the decision to discontinue Synpheny-3. As of December 31, 2023, Synlogic had cash, cash equivalents, and short-term marketable securities of $47.7 million.
Dow Jones · 03/19 11:00
*Synlogic 4Q Rev $2.77M >SYBX
Dow Jones · 03/19 11:00
*Synlogic 4Q Loss/Shr $1.71 >SYBX
Dow Jones · 03/19 11:00
Weekly Report: what happened at SYBX last week (0311-0315)?
Weekly Report · 03/18 12:03
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/13 13:05
Weekly Report: what happened at SYBX last week (0304-0308)?
Weekly Report · 03/11 11:59
Weekly Report: what happened at SYBX last week (0226-0301)?
Weekly Report · 03/04 12:02
Weekly Report: what happened at SYBX last week (0219-0223)?
Weekly Report · 02/26 12:20
Synlogic Announces Top Executive Departures and Compensation Deals
TipRanks · 02/22 21:54
Synlogic Enacts Shareholder Rights Plan for Equitable Control
TipRanks · 02/20 21:26
More
Webull provides a variety of real-time SYBX stock news. You can receive the latest news about Synlogic through multiple platforms. This information may help you make smarter investment decisions.
About SYBX
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.